Latest Period
Q1 2026
Security Snapshot
Abivax S.A. - Ordinary Shares, par value EUR0.01 per share (ABVX) Institutional Ownership
CUSIP: 00370M103
13F Institutional Holders and Ownership History from Q4 2023 to Q2 2026
Institutions Reporting
254
Shares (Excl. Options)
50,037,731
Price
$111.35
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Ordinary Shares, par value EUR0.01 per share
- Symbol
- ABVX on Nasdaq
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 50,037,731
- Total 13F value
- $5,531,098,968
- Portfolio coverage rank
- 0.03%
- Share change
- -6,355,013
- Value change
- -$766,721,986
- Number of holders
- 254
- Shares outstanding
- 82,228,907
- SEC-reported price per share
- $133.26
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
2 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- ABVX - Abivax S.A. - Ordinary Shares, par value EUR0.01 per share is tracked under CUSIP 00370M103.
- 254 institutions reported positions in Q1 2026.
- 5 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 254 to 52 between Q1 2026 and Q2 2026.
- SEC-reported value moved from $5,531,098,968 to $81,968,944.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 254 institutions filings for Q1 2026.
Security key
00370M103
Latest holder period
Q1 2026
13F holders
254
13D/G owners
5
CIK / CUSIP context first
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 00370M103:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
5
Security
ABVX
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| TCG Crossover GP I, LLC | 9.1% | $603,774,500 | 7,111,596 | Chen Yu | 30 Sep 2025 | |||
| Invus Global Management, LLC | 5% | -39% | $469,347,122 | -$177,185,644 | 3,922,995 | -27% | Invus Public Equities, L.P. | 31 Dec 2025 |
| Sofinnova Crossover I | 4.3% | -34% | $471,190,328 | -$261,676,160 | 3,535,843 | -36% | Sofinnova Crossover I SLP | 02 Jul 2026 |
| Deep Track Capital, LP | 4.8% | $28,885,195 | 3,480,144 | Deep Track Capital, LP | 30 Jun 2025 | |||
| Venrock Healthcare Capital Partners III, L.P. | 0.8% | $48,964,292 | 576,729 | Venrock Healthcare Capital Partners III, L.P. | 30 Sep 2025 |
As of 31 Mar 2026, 254 institutional investors reported holding 50,037,731 shares of Abivax S.A. - Ordinary Shares, par value EUR0.01 per share (ABVX). This represents 61% of the company’s total 82,228,907 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
43%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| TCG Crossover Management, LLC | 7.9% | 6,481,085 | -8.9% | 21% | $721,668,815 |
| UBS Group AG | 5.5% | 4,547,406 | +2.8% | 0.09% | $506,353,658 |
| Darwin Global Management, Ltd. | 4.2% | 3,468,657 | +9.1% | 9.3% | $352,068,686 |
| MORGAN STANLEY | 2.1% | 1,704,958 | -46% | 0.01% | $189,847,183 |
| Vestal Point Capital, LP | 1.8% | 1,500,000 | -21% | 4.7% | $167,025,000 |
| Caligan Partners LP | 1.8% | 1,461,924 | +0.69% | 12% | $162,785,237 |
| ADAR1 Capital Management, LLC | 1.7% | 1,394,019 | +5.8% | 9.4% | $155,224,016 |
| WESTFIELD CAPITAL MANAGEMENT CO LP | 1.6% | 1,322,938 | +31% | 0.62% | $147,309,146 |
| FMR LLC | 1.6% | 1,286,373 | -5.8% | 0.01% | $143,237,633 |
| Helikon Investments Ltd | 1.2% | 1,013,324 | 4.3% | $112,833,627 | |
| Eversept Partners, LP | 1.1% | 934,423 | +42% | 6.9% | $104,048,001 |
| JANUS HENDERSON GROUP PLC | 1.1% | 878,829 | +32% | 0.05% | $98,007,010 |
| BAKER BROS. ADVISORS LP | 1.1% | 875,796 | 0% | 0.56% | $97,519,885 |
| LORD, ABBETT & CO. LLC | 1% | 854,920 | +0.61% | 0.31% | $95,195,000 |
| Paradigm Biocapital Advisors LP | 0.94% | 772,473 | -46% | 1.8% | $86,014,869 |
| Nationale-Nederlanden Powszechne Towarzystwo Emerytalne S.A. | 0.93% | 765,915 | +11% | 7.2% | $85,284,635 |
| Cormorant Asset Management, LP | 0.92% | 760,000 | -44% | 4.3% | $84,626,000 |
| BANK OF AMERICA CORP /DE/ | 0.89% | 735,729 | +41% | 0.01% | $81,923,424 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 0.84% | 691,670 | +6.1% | 0.01% | $77,018,000 |
| Octagon Capital Advisors LP | 0.82% | 677,000 | -10% | 8.3% | $75,383,950 |
| Logos Global Management LP | 0.82% | 675,000 | +69% | 3.9% | $75,161,250 |
| Point72 Asset Management, L.P. | 0.78% | 637,736 | -74% | 0.12% | $71,011,904 |
| JPMORGAN CHASE & CO | 0.77% | 635,066 | +39% | 0% | $64,459,222 |
| Ensign Peak Advisors, Inc | 0.77% | 631,838 | +22% | 0.13% | $70,355,161 |
| MILLENNIUM MANAGEMENT LLC | 0.74% | 605,992 | -18% | 0.05% | $67,477,209 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
11
Latest
Q1 2026
Rows shown
1-11 of 11
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q2 | 648,829 | $81,968,944 | +$10,744,724 | $133.26 | 52 |
| 2026 Q1 | 50,037,731 | $5,531,098,968 | -$766,721,986 | $111.35 | 254 |
| 2025 Q4 | 56,312,422 | $7,607,004,075 | +$630,821,272 | $134.86 | 247 |
| 2025 Q3 | 51,964,814 | $4,408,157,076 | +$2,126,922,733 | $84.90 | 165 |
| 2025 Q2 | 30,664,346 | $234,581,803 | -$5,694,979 | $7.65 | 43 |
| 2025 Q1 | 31,761,546 | $198,509,815 | +$9,164,590 | $6.25 | 46 |
| 2024 Q4 | 29,861,029 | $218,582,712 | +$7,328,424 | $7.32 | 47 |
| 2024 Q3 | 27,383,884 | $312,847,988 | -$8,252,199 | $11.52 | 40 |
| 2024 Q2 | 28,098,910 | $371,643,391 | +$62,450,093 | $13.22 | 38 |
| 2024 Q1 | 23,372,028 | $334,151,423 | +$31,771,567 | $14.30 | 36 |
| 2023 Q4 | 21,265,859 | $227,821,381 | +$227,821,381 | $10.70 | 30 |